Grantham, Mayo, Van Otterloo & Co (GMO)
PCRX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Pacira BioSciences PCRX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-14,300
Closed -$750K – 811
2020
Q2 		$750K Sell
14,300
-26,200
-65% -$1.09M 0.01% 575
2020
Q1 		$1.36M Buy
+40,500
New +$1.68M 0.01% 458

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s PCRX Position: Q3 2020 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 14,300 shares — an estimated $750K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in PCRX in Q1 2020 and held it in 2 quarters. The position peaked at $1.36M in Q1 2020. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 14,300 Pacira BioSciences shares in Q3 2020, an estimated $750K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Pacira BioSciences in Q1 2020 and held it in 2 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Pacira BioSciences position peaked at $1.36M in Q1 2020.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2020, filed 13 Nov 2020.